Page last updated: 2024-11-12

casopitant

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	9917021
CHEMBL ID	1672054
CHEBI ID	135967
SCHEMBL ID	425342
MeSH ID	M0525464

Synonyms (28)

Synonym
bdbm50336575
cis-(1''-acetyl-n-{(1r)-1-[3,5-bis(trifluoromethyl)phenyl]-ethyl}-2-(4-fluoro-2-methylphenyl)-n-methyl-4,4''-bipiperidine-1-carboxamide
gw-679769
zunrisa
casopitant
CHEBI:135967
gw679769
CHEMBL1672054 ,
414910-27-3
gw 679769
casopitant [inn]
3b03kpm27l ,
unii-3b03kpm27l
1-piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-n-((1r)-1-(3,5-bis(trifluoromethyl)phenyl)ethyl)-2-(4-fluoro-2-methylphenyl)-n-methyl-, (2r,4s)-
852393-14-7
casopitant [mart.]
casopitant [who-dd]
(2r,4s)-4-(4-acetylpiperazin-1-yl)-n-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-n-methylpiperidine-1-carboxamide
rezonic (proposed trade name)
gtpl5758
zunrisa (proposed trade name)
SCHEMBL425342
NCGC00386657-01
Q5049003
DB06634
DTXSID40961762
xggtzckqrwxchw-wmtvxvaqsa-n
EN300-19880551

Research Excerpts

Overview

Casopitant mesylate is a novel, oral neurokinin-1 receptor antagonist. It has shown clinical efficacy in the prevention of chemotherapy-induced and postoperative-induced nausea and vomiting. Casopitant is a dose- and duration-dependent weak to moderate inhibitor of CYP3A.

Excerpt	Reference	Relevance
"Casopitant is shown to be a substrate, an inhibitor, and an inducer of CYP3A4, and, because of this complex behavior, it was difficult to identify the primary mechanism by which it may give rise to drug-drug interactions (DDIs) of clinical relevance."	( Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4. Bonomo, F; Motta, P; Pagliarusco, S; Pellegatti, M; Pons, N, 2011)	2.53
"Casopitant mesylate is a novel, oral neurokinin-1 receptor antagonist with demonstrated antiemetic efficacy. "	( Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Bandekar, RR; Dediu, M; Grunberg, SM; Ramlau, R; Roila, F; Rolski, J; Russo, MW, 2009)	2.02
"Casopitant is a dose- and duration-dependent weak to moderate inhibitor of CYP3A."	( Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine. Adams, LM; Fernandes, SA; Fina, P; Fiore, M; Johnson, BM; Pagliarusco, S; Peroni, M; Zamuner, S, 2010)	2.08
"Casopitant is a potent and selective NK-1 receptor antagonist that has shown clinical efficacy in the prevention of chemotherapy-induced and postoperative-induced nausea and vomiting."	( The potential role for corticosterone in the induction of cleft palate in mice after treatment with a selective NK-1 receptor antagonist, casopitant (GW679769B). Apostoli, AR; Clark, RL; Solomon, HM; Stanislaus, D; White, TE; Ziejewski, MK, 2012)	2.02

Toxicity

Excerpt	Reference	Relevance
" Adverse events occurred in 205 (77%) patients in the single-dose oral casopitant mesylate group and 203 (75%) patients in the 3-day intravenous and oral casopitant mesylate group compared with 194 (73%) of patients in the control group."	( Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-contr Aziz, Z; Grunberg, SM; Guckert, M; Herrstedt, J; Lane, S; Rolski, J; Russo, MW; Strausz, J; Wissel, P; Wright, O, 2009)	0.9
" All active doses seemed to be well tolerated; headache, dizziness, and constipation were the most frequently reported adverse events."	( Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. Blackburn, L; Chung, F; Johnson, B; Kutsogiannis, DJ; Lane, SR; Levin, J; Pergolizzi, JV; Singla, NK; Singla, SK, 2010)	0.58

Pharmacokinetics

The largest changes in hydrodolasetron exposure after coadministration with casopitant were seen in CYP2D6 EMs. Venous blood samples were taken prior to and following oral dosing up to 24 h for a pharmacokinetic study.

Excerpt	Reference	Relevance
" The additional pharmacodynamic benefit of the combination dose was not because of an alteration in the pharmacokinetics of either agent but is likely the result of the complementary mechanisms of pharmacologic action of the two drugs."	( Pharmacokinetics and brain penetration of casopitant, a potent and selective neurokinin-1 receptor antagonist, in the ferret. Bambal, R; Davis, CB; Gontarek, RR; Han, C; King, AG; Mencken, T; Minthorn, E; Rominger, D; Shu, A, 2008)	0.61
" Log-transformed area under the curve (AUC) and Cmax were statistically analyzed by performing an analysis of variance."	( Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron. Adams, LM; Johnson, B; Kirby, LC; Lebowitz, P; Stoltz, R; Yue, L; Zhang, K, 2009)	0.76
" Venous blood samples were taken prior to and following oral dosing up to 24 h for a pharmacokinetic study of casopitant concentration in plasma."	( A pharmacokinetic PET study of NK₁ receptor occupancy. Bani, M; Cunningham, VJ; Fernandes, SA; Gomeni, R; Gunn, RN; Rabiner, EA; Ratti, E; Zamuner, S, 2012)	0.59

Compound-Compound Interactions

Excerpt	Reference	Relevance
"This randomized, double-blind, dose-ranging, placebo-controlled, phase 2 trial evaluated the neurokinin-1 receptor antagonist casopitant mesylate in combination with ondansetron/dexamethasone (ond/dex) for the prevention of chemotherapy-induced nausea and vomiting (CINV) related to moderately emetogenic chemotherapy (MEC)."	( Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemothera Albert, I; Arpornwirat, W; Bandekar, RR; Grunberg, SM; Hansen, VL; Levin, J, 2009)	0.79

Bioavailability

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Dosage Studied

Casopitant was rapidly absorbed, with plasma and brain concentrations being approximately equal at 2 h postdose. Venous blood samples were taken prior to and following oral dosing up to 24 h for a pharmacokinetic study of casopitant concentration in plasma.

Excerpt	Relevance	Reference
" dosing to the ferret, casopitant was rapidly absorbed, with plasma and brain concentrations being approximately equal at 2 h postdose."	( Pharmacokinetics and brain penetration of casopitant, a potent and selective neurokinin-1 receptor antagonist, in the ferret. Bambal, R; Davis, CB; Gontarek, RR; Han, C; King, AG; Mencken, T; Minthorn, E; Rominger, D; Shu, A, 2008)	0.92
" The distribution and metabolism of casopitant were studied in both species evaluating the accumulation of drug-related material (DRM) after repeat dosing and its potential relationship with pathological findings observed in myocardium."	( Tissue distribution and characterization of drug-related material in rats and dogs after repeated oral administration of casopitant. Bordini, E; Cufari, D; Ferrari, L; Martinucci, S; Miraglia, L; Pagliarusco, S; Pellegatti, M, 2011)	0.85
" Venous blood samples were taken prior to and following oral dosing up to 24 h for a pharmacokinetic study of casopitant concentration in plasma."	( A pharmacokinetic PET study of NK₁ receptor occupancy. Bani, M; Cunningham, VJ; Fernandes, SA; Gomeni, R; Gunn, RN; Rabiner, EA; Ratti, E; Zamuner, S, 2012)	0.59

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
piperidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	6.0081	0.0123	7.9835	43.2770	AID1645841
G	Vesicular stomatitis virus	Potency	9.5221	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	26.8370	0.0010	8.3798	61.1304	AID1645840
Interferon beta	Homo sapiens (human)	Potency	9.5221	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	9.5221	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	9.5221	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	9.5221	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Substance-P receptor	Homo sapiens (human)	Ki	0.0002	0.0000	0.7936	8.7470	AID576859; AID577014
Sigma non-opioid intracellular receptor 1	Homo sapiens (human)	Ki	2.9800	0.0000	0.4901	10.0000	AID577016
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 3A4	Homo sapiens (human)	Km	10.1000	1.9300	5.9060	8.7000	AID1216301
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (107)

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
aggressive behavior	Substance-P receptor	Homo sapiens (human)
positive regulation of leukocyte migration	Substance-P receptor	Homo sapiens (human)
angiotensin-mediated drinking behavior	Substance-P receptor	Homo sapiens (human)
inflammatory response	Substance-P receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Substance-P receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Substance-P receptor	Homo sapiens (human)
tachykinin receptor signaling pathway	Substance-P receptor	Homo sapiens (human)
long-term memory	Substance-P receptor	Homo sapiens (human)
associative learning	Substance-P receptor	Homo sapiens (human)
detection of abiotic stimulus	Substance-P receptor	Homo sapiens (human)
response to ozone	Substance-P receptor	Homo sapiens (human)
positive regulation of epithelial cell migration	Substance-P receptor	Homo sapiens (human)
response to auditory stimulus	Substance-P receptor	Homo sapiens (human)
regulation of smooth muscle cell migration	Substance-P receptor	Homo sapiens (human)
positive regulation of synaptic transmission, cholinergic	Substance-P receptor	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Substance-P receptor	Homo sapiens (human)
response to estradiol	Substance-P receptor	Homo sapiens (human)
response to progesterone	Substance-P receptor	Homo sapiens (human)
response to nicotine	Substance-P receptor	Homo sapiens (human)
operant conditioning	Substance-P receptor	Homo sapiens (human)
sperm ejaculation	Substance-P receptor	Homo sapiens (human)
eating behavior	Substance-P receptor	Homo sapiens (human)
positive regulation of vascular permeability	Substance-P receptor	Homo sapiens (human)
response to ethanol	Substance-P receptor	Homo sapiens (human)
positive regulation of action potential	Substance-P receptor	Homo sapiens (human)
positive regulation of blood pressure	Substance-P receptor	Homo sapiens (human)
positive regulation of ossification	Substance-P receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Substance-P receptor	Homo sapiens (human)
positive regulation of hormone secretion	Substance-P receptor	Homo sapiens (human)
behavioral response to pain	Substance-P receptor	Homo sapiens (human)
regulation of smooth muscle cell proliferation	Substance-P receptor	Homo sapiens (human)
positive regulation of lymphocyte proliferation	Substance-P receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Substance-P receptor	Homo sapiens (human)
positive regulation of stress fiber assembly	Substance-P receptor	Homo sapiens (human)
response to electrical stimulus	Substance-P receptor	Homo sapiens (human)
smooth muscle contraction involved in micturition	Substance-P receptor	Homo sapiens (human)
positive regulation of uterine smooth muscle contraction	Substance-P receptor	Homo sapiens (human)
positive regulation of flagellated sperm motility	Substance-P receptor	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
lipid transport	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nervous system development	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
regulation of neuron apoptotic process	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
protein homotrimerization	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (43)

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
tachykinin receptor activity	Substance-P receptor	Homo sapiens (human)
protein binding	Substance-P receptor	Homo sapiens (human)
substance P receptor activity	Substance-P receptor	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
G protein-coupled opioid receptor activity	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
protein binding	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (38)

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
plasma membrane	Substance-P receptor	Homo sapiens (human)
cell surface	Substance-P receptor	Homo sapiens (human)
dendrite	Substance-P receptor	Homo sapiens (human)
sperm flagellum	Substance-P receptor	Homo sapiens (human)
cell body	Substance-P receptor	Homo sapiens (human)
sperm head	Substance-P receptor	Homo sapiens (human)
sperm midpiece	Substance-P receptor	Homo sapiens (human)
plasma membrane	Substance-P receptor	Homo sapiens (human)
sperm midpiece	Substance-P receptor	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nuclear envelope	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nuclear inner membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nuclear outer membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
lipid droplet	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
cytosol	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
postsynaptic density	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
growth cone	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
cytoplasmic vesicle	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
anchoring junction	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
postsynaptic density membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (89)

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1216338	Metabolism dependent inhibition of CYP3A4 in human liver microsomes pretreated with compound for 20 mins in presence of midazolam substrate and NADPH by HPLC-MS/MS method relative to untreated control	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577033	Oral bioavailability in rat at 1 mg/kg	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID779999	Plasma clearance in rat at 0.5 mg/kg, iv and 1 mg/kg, po	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
AID577023	Toxicity in Mongolian gerbil assessed as abnormal behavior at 0.3 to 1 mg/kg, po	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID577044	Half life in marmoset at 1 mg/kg, iv	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID577029	Oral bioavailability in mouse at 2 mg/kg	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID779992	Oral bioavailability in dog at 1 mg/kg	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
AID1216318	Tmax in healthy human at 150 mg, po administered as single dose	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577025	Toxicity in Mongolian gerbil assessed as locomotor activity at 1 mg/kg, po	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216315	AUC (0 to t) in healthy human at 150 mg, po administered as single dose on day 8 and cotreated with rifampin at 600 mg, po qd on day 1 to 9	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577036	Half life in dog at 0.5 mg/kg, iv	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216332	Ratio of drug level in blood to plasma in human	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID1216321	Half life in healthy human at 150 mg, po administered as single dose on day 8 and cotreated with rifampin at 600 mg, po qd on day 1 to 9	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577045	Bioavailability in marmoset at 1 mg/kg, iv	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216344	Unbound fraction in human gut	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID1216340	Metabolism dependent inactivation of CYP3A4 in human liver microsomes pretreated with compound in presence of midazolam substrate and NADPH by HPLC-MS/MS method relative to untreated control	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID1216351	Cmax in healthy human assessed as fold change at 100 mg, po in presence of 400 mg ketoconazole	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577043	Volume of distribution at steady state in marmoset at 1 mg/kg, iv	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216308	Tmax in healthy human at 100 mg, po administered as single dose on day 4 and cotreated with ketoconazole at 400 mg, po qd on day 1 to 7	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577026	Plasma clearance in mouse at 2 mg/kg, po	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID577015	Displacement of [3H]GR205171 from human NK1 receptor in cortex homogenate at 0.5 nM by liquid scintillation counting	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216343	Volume of distribution at steady state in human	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577022	Antidepressant activity against po dosed Mongolian gerbil assessed as increase in social interaction time	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216333	Unbound fraction in human plasma	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577012	Inhibition of GR73632-induced foot tapping in orally dosed Mongolian gerbil after 8 hrs	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216334	Fraction drug absorption in human	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID1216316	Cmax in healthy human at 150 mg, po administered as single dose	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID779997	Volume of distribution at steady state in rat at 0.5 mg/kg, iv and 1 mg/kg, po	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
AID1216305	Cmax in healthy human at 100 mg, po administered as single dose	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID1216307	Tmax in healthy human at 100 mg, po administered as single dose	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID779996	Volume of distribution at steady state in dog at 0.5 mg/kg, iv and 1 mg/kg, po	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
AID577042	Plasma clearance in marmoset at 1 mg/kg, iv	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID577027	Volume of distribution at steady state in mouse at 2 mg/kg, po	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID779995	Half life in rat at 0.5 mg/kg, iv and 1 mg/kg, po	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
AID577009	Inhibition of GR73632-induced foot tapping in orally dosed Mongolian gerbil after 1 hr	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216306	Cmax in healthy human at 100 mg, po administered as single dose on day 4 and cotreated with ketoconazole at 400 mg, po qd on day 1 to 7	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577019	Binding affinity to calcium channel L type benzodiazepine binding site	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216341	Drug metabolism in human liver microsomes assessed as CYP3A4-mediated GSK525060 formation at 5 to 20 uM up to 30 mins by HPLC-MS/MS method	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID1216320	Half life in healthy human at 150 mg, po administered as single dose	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577037	Bioavailability in dog at 0.5 mg/kg, iv	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID577016	Binding affinity to sigma 1 receptor	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216336	Inhibition of CYP3A4 in human liver microsomes using midazolam substrate by HPLC-MS/MS method	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID1216354	AUC in healthy human assessed as fold change at 150 mg, po in presence of 600 mg rifampin	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID1216301	Drug metabolism assessed as human recombinant CYP3A4-mediated GSK525060 formation after 30 mins by HPLC-MS/MS method	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577028	Half life in mouse at 2 mg/kg, po	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216352	AUC in healthy human assessed as fold change at 100 mg, po in presence of 400 mg ketoconazole	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID576859	Displacement of [3H]SP from human NK1 receptor expressed in CHO cells by liquid scintillation counting	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID577041	Bioavailability in cynomolgus monkey at 1 mg/kg, iv	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID779998	Plasma clearance in dog at 0.5 mg/kg, iv and 1 mg/kg, po	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
AID1216299	Drug metabolism assessed as human recombinant CYP3A4-mediated GSK525060 formation at 10 uM after 30 mins by HPLC-MS/MS method	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577017	Binding affinity to sodium channel site 2	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216304	AUC (0 to t) in healthy human at 100 mg, po administered as single dose	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577038	Plasma clearance in cynomolgus monkey at 1 mg/kg, iv	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216319	Tmax in healthy human at 150 mg, po administered as single dose on day 8 and cotreated with rifampin at 600 mg, po qd on day 1 to 9	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577034	Plasma clearance in dog at 0.5 mg/kg, iv	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID577014	Displacement of [3H]GR205171 from human NK1 receptor in cortex homogenate by liquid scintillation counting	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216337	Inhibition of CYP3A4 in human liver microsomes using nifedipine substrate by HPLC-MS/MS method	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID1216317	Cmax in healthy human at 150 mg, po administered as single dose on day 8 and cotreated with rifampin at 600 mg, po qd on day 1 to 9	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID1216331	Dissociation constant, pKa of the compound	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID1216346	Fraction of drug metabolized assessed as human CYP3A4-mediated drug metabolism	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577021	Antidepressant activity against Mongolian gerbil assessed as increase in social interaction time at 0.3 to 1 mg/kg, po	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID779993	Oral bioavailability in rat at 1 mg/kg	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
AID577018	Binding affinity to calcium channel L type dihydropyridine binding site	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216314	AUC (0 to t) in healthy human at 150 mg, po administered as single dose	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577030	Plasma clearance in rat at 1 mg/kg, iv and po	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216345	Intrinsic clearance in human liver microsomes assessed per mg protein	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577013	Inhibition of GR73632-induced foot tapping in orally dosed Mongolian gerbil after 24 hrs	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID577024	Antidepressant activity against po dosed Mongolian gerbil assessed as increase in social interaction time at 1 mg/kg, po (Rbv = 19+/-1.2seconds)	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216302	Drug metabolism assessed as human recombinant CYP3A4-mediated GSK525060 formation per pmol of protein after 30 mins by HPLC-MS/MS method	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577035	Volume of distribution at steady state in dog at 0.5 mg/kg, iv	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216297	Drug metabolism in human liver microsomes assessed as CYP3A4-mediated GSK525060 formation after 30 mins by HPLC-MS/MS method	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID1216330	Lipophilicity, log P of the compound	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577011	Inhibition of GR73632-induced foot tapping in sc dosed Mongolian gerbil after 1 hr	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216298	Drug metabolism in human liver microsomes assessed as CYP3A4-mediated GSK525060 formation per pmol of protein after 30 mins by HPLC-MS/MS method	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID779994	Half life in dog at 0.5 mg/kg, iv and 1 mg/kg, po	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
AID577031	Volume of distribution at steady state in rat at 1 mg/kg, iv and po	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID577039	Volume of distribution at steady state in cynomolgus monkey at 1 mg/kg, iv	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216353	Cmax in healthy human assessed as fold change at 150 mg, po in presence of 600 mg rifampin	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577040	Half life in dog at cynomolgus monkey at 1 mg/kg, iv	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216303	AUC (0 to t) in healthy human at 100 mg, po administered as single dose on day 4 and cotreated with ketoconazole at 400 mg, po qd on day 1 to 7	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID577032	Half life in rat at 1 mg/kg, iv and po	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clini
AID1216339	Metabolism dependent inhibition of CYP3A4 in human liver microsomes pretreated with compound for 20 mins in presence of nifedipine substrate and NADPH by HPLC-MS/MS method relative to untreated control	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
AID1346346	Human NK1 receptor (Tachykinin receptors)	2010	Expert opinion on therapeutic patents, Aug, Volume: 20, Issue:8	Neurokinin-1 receptor antagonists: a comprehensive patent survey.
AID1346346	Human NK1 receptor (Tachykinin receptors)	2013	Journal of receptor and signal transduction research, Dec, Volume: 33, Issue:6	Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (43)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	12 (27.91)	29.6817
2010's	29 (67.44)	24.3611
2020's	2 (4.65)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	26.18 (24.57)
Research Supply Index	4.11 (2.92)
Research Growth Index	4.50 (4.65)
Search Engine Demand Index	31.58 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (26.18)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	17 (39.53%)	5.53%
Reviews	7 (16.28%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	19 (44.19%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (30)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of GW679769 (30mg and 90mg) on Sleep Continuity, PSG Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Subjects With Primary Insomnia [NCT00650871]	Phase 2	48 participants (Actual)	Interventional	2004-07-30	Completed
A Study of Single Dose Intravenous Casopitant in Combination With Ondansetron and Dexamethasone for the Prevention of Oxaliplatin Induced Nausea and Vomiting. [NCT00601172]	Phase 3	710 participants (Actual)	Interventional	2008-03-10	Completed
A Study of Single Dose Intravenous Casopitant in Combination With Ondansetron and Dexamethasone for the Prevention of Cisplatin-Induced Nausea and Vomiting [NCT00891761]	Phase 3	0 participants (Actual)	Interventional	2009-09-30	Withdrawn(stopped due to This study has been cancelled prior to enrollment.)
See Detailed Description [NCT00169572]	Phase 2	492 participants	Interventional	2005-02-28	Completed
A Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Effects of GW679769 on Polysomnographic Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Elderly and Non-elderly Subjects With Primary Insomni [NCT00280436]	Phase 2	122 participants (Actual)	Interventional	2006-01-31	Completed
An Open-Label, Phase I Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Intravenous and Oral Doses of Dexamethasone and Intravenous and Oral Doses of Ondansetron When Administered in Healthy Adult Subjects [NCT00437229]	Phase 1	37 participants (Actual)	Interventional	2007-02-19	Completed
An Open-Label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of [Rifampin] on the Pharmacokinetics of a Single Oral Dose of [GW679769] [NCT00405080]	Phase 1	12 participants (Actual)	Interventional	2006-11-11	Completed
A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist Casopitant (GW679769) in Combination With Ondansetron a [NCT00366834]	Phase 3	1,840 participants (Actual)	Interventional	2006-07-31	Completed
A Phase I, Randomized, Double-Blind Study to Assess the Effects of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of Repeat Oral Dosing of Casopitant in Healthy Subjects [NCT00460707]	Phase 1	85 participants (Actual)	Interventional	2007-04-16	Completed
An Open-Label, Three-Part, Two Period, Single Sequence Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Repeat Oral Doses of Dolasetron, Granisetron or Rosiglitazone When Co-Administered in Healthy Adult Subjects [NCT00511823]	Phase 1	16 participants (Actual)	Interventional	2007-07-23	Completed
An Exploratory Study to Investigate the Effects of the NK1 Antagonist GW679769, 60 mg Once Daily for 4 Days, on Gastric Accommodation, Gastric Emptying and Gastric Distension-induced Perception and Discomfort in Adult Male and Female Patients With Functio [NCT00358410]	Phase 2	13 participants (Actual)	Interventional	2006-01-31	Completed
A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study of the Safety and Efficacy of the Oral NeuroKinin-1 Receptor Antagonist, GW679769 in Combination With Ondansetron Hydrochloride and Dexamethasone for [NCT00104403]	Phase 2	722 participants (Actual)	Interventional	2004-12-31	Completed
An Outpatient, Randomised, Double-blind, Placebo Controlled, Parallel Group Exploratory Study to Evaluate Safety, Tolerability and Efficacy of GW679769 in Patients With Fibromyalgia Syndrome Comorbid With Depression. [NCT00264628]		8 participants (Actual)	Observational	2005-10-31	Completed
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder. [NCT00102492]	Phase 2	356 participants (Actual)	Interventional	2004-10-31	Completed
A Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety and Efficacy of Oral Dosing With GW679769 (50 mg or 150 mg) for Three Consecutive Days When Administered With a Single Intravenous Dose of O [NCT00274690]	Phase 2	435 participants (Actual)	Interventional	2005-02-28	Completed
A 28 Day, Polysomnographic and Subjective Assessment of GW679769 for the Treatment of Primary Insomnia: A Randomized, Double-blind, Parallel-Group, Placebo-Controlled Trial. [NCT00280423]	Phase 2	342 participants (Actual)	Interventional	2006-01-31	Completed
A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50mg Oral Dosing With the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects [NCT00326248]	Phase 3	482 participants (Actual)	Interventional	2006-03-31	Completed
A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant, Administered in Combination With ZOFRAN and [NCT00431236]	Phase 3	810 participants (Actual)	Interventional	2006-11-06	Completed
A Phase I, Open-Label, Randomized, Two Period Crossover Study to Investigate the Effects of GW679769 on the Pharmacokinetics of Docetaxel in Subjects With Cancer [NCT00440128]	Phase 1	12 participants (Actual)	Interventional	2007-05-04	Completed
An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Steady-State Warfarin When Co-administered With Repeat Doses of Casopitant [GW679769] in Healthy Adult Subjects. [NCT00404274]	Phase 1	97 participants (Actual)	Interventional	2006-11-01	Completed
An Open-label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of a Single Oral Dose of [GW679769] [NCT00404378]	Phase 1	15 participants (Actual)	Interventional	2006-10-20	Completed
An Open Label, Repeat Dose, Randomized, Two Period Crossover Study to Investigate the Potential Pharmacokinetic Interactions Between Oral GW679769 and Intravenous Cyclophosphamide in Cancer Patients [NCT00334646]	Phase 1	25 participants (Actual)	Interventional	2005-08-10	Terminated(stopped due to compound terminated)
A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects With Major Depressive Disorder (MDD) [NCT00413023]	Phase 2	348 participants (Actual)	Interventional	2005-06-30	Completed
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms [NCT00321477]	Phase 2	160 participants (Anticipated)	Interventional	2005-12-31	Completed
See Detailed Description [NCT00332319]	Phase 2	1 participants (Actual)	Interventional	2006-01-31	Terminated
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female [NCT00334152]	Phase 3	515 participants (Actual)	Interventional	2006-03-31	Completed
A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Morning Administration of GW679769 (10mg and 30 mg) on Polysomnograph Sleep Recordings, Subjective Sleep Assessment, Daytime Cognition and Psychomotor Function in S [NCT00354809]	Phase 2	68 participants (Actual)	Interventional	2006-05-31	Completed
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects With Hepatic Impairment [NCT00359177]	Phase 1	24 participants (Actual)	Interventional	2005-12-01	Completed
A Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Parallel Group, fMRI Study Comparing BOLD Activation Patterns Before and After 12 Weeks of Treatment With Placebo, Comparator and GW679769 in Subjects With Social Anxiety Disorder (SAD). [NCT00332046]	Phase 1	57 participants	Interventional	2006-01-31	Completed
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects With Renal Impairment [NCT00358813]	Phase 1	18 participants (Actual)	Interventional	2006-09-08	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00601172 (25) [back to overview]	Percentage of Participants Who Achieved a Complete Response in the Acute Phase of Cycle 1
NCT00601172 (25) [back to overview]	Percentage of Participants Who Achieved a Complete Response in the Delayed Phase of Cycle 1
NCT00601172 (25) [back to overview]	Percentage of Participants Who Achieved a Complete Response in the Overall Phase (0-120 Hours) Following Initiation of the First Cycle of an Oxaliplatin Based Moderately Emetogenic Chemotherapy (MEC) Regimen
NCT00601172 (25) [back to overview]	Percentage of Participants Who Achieved a Complete Response in the Overall Phase of Cycle 2
NCT00601172 (25) [back to overview]	Single-dose Pharmacokinetic Parameters: Clearance (CL) for Casopitant
NCT00601172 (25) [back to overview]	Single-dose Pharmacokinetic Parameters: Volume of Distribution (Vdss) for Casopitant
NCT00601172 (25) [back to overview]	Time to First Anti-emetic Rescue Medication
NCT00601172 (25) [back to overview]	Time to First Emetic Event
NCT00601172 (25) [back to overview]	Evaluation of Vital Signs: Mean Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
NCT00601172 (25) [back to overview]	Evaluation of Vital Signs: Mean Heart Rate
NCT00601172 (25) [back to overview]	Maximum Nausea Score, Assessed by a Visual Analogue Scale (VAS)
NCT00601172 (25) [back to overview]	Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
NCT00601172 (25) [back to overview]	Number of Participants With Clinical Chemistry Toxicity Grade Shifts From Baseline to Toxicity Grade 3 and 4
NCT00601172 (25) [back to overview]	Number of Participants With Hematology Toxicity Grade Shifts From Baseline to Toxicity Grade 3 and 4
NCT00601172 (25) [back to overview]	Percentage of Participants Who Achieved Complete Protection Defined as Complete Responders With no Significant Nausea
NCT00601172 (25) [back to overview]	Percentage of Participants Who Achieved Total Control, Defined as Complete Responders Who Had no Nausea
NCT00601172 (25) [back to overview]	Percentage of Participants Who Received Rescue Medication
NCT00601172 (25) [back to overview]	Percentage of Participants Who Reported Nausea, Defined as a Maximum Score of >= 5 mm on the VAS
NCT00601172 (25) [back to overview]	Percentage of Participants Who Reported Significant Nausea, Defined as a Maximum Score >= 25 mm on the VAS
NCT00601172 (25) [back to overview]	Percentage of Participants Who Vomited and/or Retched
NCT00601172 (25) [back to overview]	Percentage of Participants Whose Daily Life Activities Were Impacted in the Overall Phase of Cycle 1, Assessed by Functional Living Index-Emesis (FLIE) Questionnaire
NCT00601172 (25) [back to overview]	Single-dose Pharmacokinetic (PK) Parameters: Area Under the Curve (AUC) 0 to Infinity (0-∞), AUC 0 to t (0-t) and AUC 0 to 24 Hours (0-24) for Casopitant; AUC (0-t) and AUC (0-24) for Metabolites GSK525060, GSK517142 and GSK631832
NCT00601172 (25) [back to overview]	Single-dose Pharmacokinetic Parameters: Maximum Observed Drug Concentration (Cmax) for Casopitant and Metabolites GSK525060, GSK517142 and GSK631832
NCT00601172 (25) [back to overview]	Single-dose Pharmacokinetic Parameters: Time to Maximum Observed Drug Concentration (Tmax) and Observed Elimination Half-life (t1/2) for Casopitant and Metabolites GSK525060, GSK517142 and GSK631832
NCT00601172 (25) [back to overview]	Severity of Nausea in the Overall, Acute, and Delayed Phases of Cycle 1 Assessed by a Categorical Scale

Percentage of Participants Who Achieved a Complete Response in the Acute Phase of Cycle 1

Complete response was defined as no vomiting, no retching and no use of anti-emetic rescue medication. Participants who vomited or retched or received rescue medication in the acute phase (0- 24 hours) following administration of oxaliplatin were also considered as complete response failures in the subsequent delayed (24-120 hour) time period, irrespective of actual response in the delayed phase. However, participants who vomited or retched or received rescue medication in the delayed (24-120 hours) phase were not considered as failures in the acute (0-24 hours) phase. Percentage of participants who achieved a complete response in the acute phase of Cycle 1 are presented. (NCT00601172)
Timeframe: 0 to 24 hours in the first cycle of chemotherapy

Intervention	Percentage of participants (Number)
Placebo	96
Casopitant 90 mg	97

Intervention	Millimeters of mercury (mmHg) (Mean)
	DBP: Cycle 1, post-oxaliplatin	DBP: Cycle 1, End of cycle	DBP: Cycle 2, post-oxaliplatin	DBP: Cycle 2, End of cycle	DBP: Cycle 3, post-oxaliplatin	DBP: Cycle 3, End of cycle	DBP: Cycle 4, post-oxaliplatin	DBP: Cycle 4, End of cycle	DBP: Cycle 5, post-oxaliplatin	DBP: Cycle 5, End of cycle	DBP: Cycle 6, post-oxaliplatin	DBP: Cycle 6, End of cycle	SBP: Cycle 1, post-oxaliplatin	SBP: Cycle 1, End of cycle	SBP: Cycle 2, post-oxaliplatin	SBP: Cycle 2, End of cycle	SBP: Cycle 3, post-oxaliplatin	SBP: Cycle 3, End of cycle	SBP: Cycle 4, post-oxaliplatin	SBP: Cycle 4, End of cycle	SBP: Cycle 5, post-oxaliplatin	SBP: Cycle 5, End of cycle	SBP: Cycle 6, post-oxaliplatin	SBP: Cycle 6, End of cycle
Casopitant 90 mg	76.5	76.5	76.8	77.1	76.6	77.2	76.9	76.4	77.7	77.7	77.6	77.5	126.8	126.7	129.3	127.8	128.7	127.7	129.0	128.3	129.7	128.8	131.5	129.1
Placebo	77.2	76.9	77.7	76.8	78.0	77.3	78.2	76.8	77.4	77.1	77.9	77.9	130.6	128.7	130.1	128.9	131.0	128.8	131.8	128.0	131.3	128.6	132.2	129.7

Intervention	Beats/minute (Mean)
	Cycle 1, post-oxaliplatin	Cycle 1, End of cycle	Cycle 2, post-oxaliplatin	Cycle 2, End of cycle	Cycle 3, post-oxaliplatin	Cycle 3, End of cycle	Cycle 4, post-oxaliplatin	Cycle 4, End of cycle	Cycle 5, post-oxaliplatin	Cycle 5, End of cycle	Cycle 6, post-oxaliplatin	Cycle 6, End of cycle
Casopitant 90 mg	73.7	75.3	73.7	74.7	72.2	75.4	72.2	74.7	72.9	75.0	73.4	75.6
Placebo	73.1	75.1	73.0	74.8	73.2	74.9	72.6	75.0	72.8	74.7	73.5	74.7

Intervention	Scores on a Scale (Mean)
	0-120 hours	0-24 hours	24-120 hours
Casopitant 90 mg	16.0	5.3	15.3
Placebo	13.5	4.3	13.0

Intervention	Participants (Count of Participants)
	ALT: All cycles, Grade 0 to 3	ALT: All cycles, Grade 2 to 3	AST: All cycles, Grade 0 to 3	High chloride: All cycles, Grade 1 to 3	Low chloride: All cycles, Grade 0 to 3	Hyperglycemia: Al cycles, Grade 0 to 3	Hyperglycemia: All cycles, Grade 1 to 3	Hyperglycemia: All cycles, Grade 2 to 3	Hyperglycemia: All cycles, Grade 3 to 3	Hypoglycemia: All cycles, Grade 0 to 4	Hyperkalemia: All cycles, Grade 2 to 3	Hyperkalemia: All cycles, Grade 4 to 3	Hyperkalemia: All cycles, Grade 0 to 3	Hyperkalemia: All cycles, Grade 0 to 4	Hypokalemia: All cycles, Grade 0 to 3	Hyponatremia: All cycles, Grade 1 to 3	Total Bilirubin: All cycles, Grade 0 to 3	Total Bilirubin: All cycles, Grade 0 to 4
Casopitant 90 mg	2	0	1	0	1	3	2	5	3	1	0	0	2	2	8	8	1	0
Placebo	1	1	0	2	0	1	1	9	3	1	1	1	0	0	6	6	1	1

Intervention	Participants (Count of Participants)
	Hematocrit: All cycles, Grade 2 to Grade 3	Hemoglobin: All cycles, Grade 1 to Grade 3	Hemoglobin: All cycles, Grade 2 to Grade 3	Hemoglobin: All cycles, Grade 3 to Grade 3	Platelet count: All cycles, Grade 0 to 3	Total Neutrophils: All cycles, Grade 0 to 3	Total Neutrophils: All cycles, Grade 1 to 3	Total Neutrophils: All cycles, Grade 2 to 3	White Blood Cell count: All cycles, Grade 0 to 3	White Blood Cell count: All cycles, Grade 1 to 3	White Blood Cell count: All cycles, Grade 2 to 3
Casopitant 90 mg	1	0	1	2	1	37	1	0	5	1	2
Placebo	0	2	3	0	1	24	0	1	10	0	1

Intervention	Percentage of participants (Number)
	Nausea impact	Vomiting impact
Casopitant 90 mg	23.7	11.5
Placebo	21.3	12.5

Intervention	Hournanogram/milliliter (hrng/mL) (Geometric Mean)
	Casopitant: AUC(0-24)	Casopitant: AUC(0-inf)	Casopitant: AUC(0-t)	GSK525060: AUC(0-24)	GSK525060: AUC(0-t)	GSK517142: AUC(0-24)	GSK517142: AUC(0-t)	GSK631832: AUC(0-24)	GSK631832: AUC(0-t)
Casopitant 90 mg	6913.626	8607.049	7688.562	2247.290	2796.734	49.964	40.997	165.550	231.018

Intervention	Nanogram/milliliter (ng/mL) (Geometric Mean)
	Casopitant	GSK525060	GSK517142	GSK631832
Casopitant 90 mg	2078.776	143.038	3.426	9.853

Intervention	Hour (Median)
	Casopitant: Tmax	Casopitant: t1/2	GSK525060: Tmax	GSK517142: Tmax	GSK631832: Tmax
Casopitant 90 mg	0.520	12.347	3.580	1.500	5.500

Intervention	Participants (Count of Participants)
	0-120 hours72379989				0-120 hours72379990	0-24 hours72379989	0-24 hours72379990	24-120 hours72379990	24-120 hours72379989
	Mild	Moderate	Severe	None
Placebo	218
Placebo	73
Casopitant 90 mg	97
Placebo	49
Casopitant 90 mg	54
Placebo	12
Casopitant 90 mg	12
Placebo	313
Casopitant 90 mg	299
Placebo	23
Casopitant 90 mg	40
Placebo	13
Casopitant 90 mg	15
Placebo	3
Casopitant 90 mg	1
Casopitant 90 mg	192

Substance	Relationship Strength	Studies	Trials	Classes	Roles
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	2.06	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	9.36	1	1	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	7.46	2	0	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	7.46	2	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
ondansetron Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.	9.72	11	10	carbazoles
piperazine [no description available]	2.06	1	0	azacycloalkane; piperazines; saturated organic heteromonocyclic parent	anthelminthic drug
corticosterone [no description available]	7.07	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
quinuclidines Quinuclidines: A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.	3.14	1	0	quinuclidines; saturated organic heterobicyclic parent
fluorobenzenes Fluorobenzenes: Derivatives of BENZENE that contain FLUORINE.. monofluorobenzene : The simplest member of the class of monofluorobenzenes that is benzene carrying a single fluoro substituent.. fluorobenzenes : Any fluoroarene that is a benzene or a substituted benzene carrying at least one fluoro group.	3.18	1	0	monofluorobenzenes	NMR chemical shift reference compound
fluorine Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.	2.06	1	0	diatomic fluorine; gas molecular entity	NMR chemical shift reference compound
paroxetine Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.	4.37	1	1	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
cp 96345 CP 96345: structure given in first source; potent nonpeptide antagonist of the substance P (NK1) receptor; CP 96344 is enantiomer of CP 96345	2.08	1	0
(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine: structure given in first source	2.08	1	0
l 733060 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine: RN given refers to (2S-cis)-isomer; L-733,061 is pharmacologically inactive; structure in first source	2.08	1	0	piperidines
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	4.37	1	1	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
troleandomycin Troleandomycin: A macrolide antibiotic that is similar to ERYTHROMYCIN.. troleandomycin : A semi-synthetic macrolide antibiotic obtained by acetylation of the three free hydroxy groups of oleandomycin. Troleandomycin is only found in individuals that have taken the drug.	2.06	1	0	acetate ester; epoxide; macrolide antibiotic; monosaccharide derivative; polyketide; semisynthetic derivative	EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor; xenobiotic
dolasetron [no description available]	9.35	1	1	indolyl carboxylic acid
granisetron Granisetron: A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic for cancer chemotherapy patients.. granisetron : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 1-methyl-1H-indazole-3-carboxylic acid with the primary amino group of (3-endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine. A selective 5-HT3 receptor antagonist, it is used (generally as the monohydrochloride salt) to manage nausea and vomiting caused by cancer chemotherapy and radiotherapy, and to prevent and treat postoperative nausea and vomiting.	9.35	1	1	aromatic amide; indazoles
palonosetron Palonosetron: Isoquinoline and quinuclidine derivative that acts as a 5-HT3 RECEPTOR antagonist. It is used in the prevention of nausea and vomiting induced by cytotoxic chemotherapy, and for the prevention of post-operative nausea and vomiting.. palonosetron : An organic heterotricyclic compound that is an antiemetic used (as its hydrochloride salt) in combination with netupitant (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.	3.14	1	0	azabicycloalkane; delta-lactam; organic heterotricyclic compound	antiemetic; serotonergic antagonist
netupitant netupitant: orally active neurokinin-1 receptor antagonist. netupitant : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoic acid with the secondary amino group of N-methyl-4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-amine; an antiemetic used in combination with palonosetron hydrochloride (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.	2.08	1	0	aminopyridine; monocarboxylic acid amide; N-alkylpiperazine; N-arylpiperazine; organofluorine compound; toluenes	antiemetic; neurokinin-1 receptor antagonist
vofopitant [no description available]	2.07	1	0
vestipitant [no description available]	3.87	3	0
orvepitant [no description available]	2.08	1	0
piperidines Piperidines: A family of hexahydropyridines.	14.51	39	17
natriuretic peptide, brain Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.	2.47	2	0	polypeptide
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	9.36	1	1	benzenes; hydroxycoumarin; methyl ketone
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	9.36	1	1	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	4.92	4	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist

Condition	Indicated	Relationship Strength	Studies	Trials
Depression, Endogenous [description not available]	0	2.06	1	0
Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.	0	2.06	1	0
Depression, Involutional Form of depression in those MIDDLE AGE with feelings of ANXIETY.	0	6.44	3	1
Chronic Insomnia [description not available]	0	3.85	2	0
Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)	1	8.44	3	1
Sleep Initiation and Maintenance Disorders Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.	1	5.85	2	0
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.25	1	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Emesis, Postoperative [description not available]	0	7.22	4	2
Bladder, Overactive [description not available]	0	2.96	1	0
Anxiety Neuroses [description not available]	0	3.37	2	0
Diffuse Myofascial Pain Syndrome [description not available]	0	2.96	1	0
Emesis [description not available]	0	11.58	13	9
Anxiety Disorders Persistent and disabling ANXIETY.	0	3.37	2	0
Fibromyalgia A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95)	0	2.96	1	0
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	1	16.17	26	18
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	1	13.58	13	9
Postoperative Nausea and Vomiting Emesis and queasiness occurring after anesthesia.	1	11.46	8	4
Urinary Bladder, Overactive Symptom of overactive detrusor muscle of the URINARY BLADDER that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. URINARY INCONTINENCE may or may not be present.	1	4.96	1	0
Adverse Drug Event [description not available]	0	5.78	2	2
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	5.78	2	2
Benign Neoplasms [description not available]	0	9.3	7	5
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	9.3	7	5
Alopecia Cicatrisata [description not available]	0	4.35	1	1
Breast Cancer [description not available]	0	4.35	1	1
Colonic Inertia Symptom characterized by the passage of stool once a week or less.	0	5.79	2	2
Bilateral Headache [description not available]	0	5.79	2	2
Alopecia Absence of hair from areas where it is normally present.	0	4.35	1	1
Breast Neoplasms Tumors or cancer of the human BREAST.	0	4.35	1	1
Constipation Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.	0	5.79	2	2
Headache The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.	0	5.79	2	2
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	0	4.35	1	1
Asthma, Bronchial [description not available]	0	2.96	1	0
Behavior Disorders [description not available]	0	2.96	1	0
Cholera Infantum [description not available]	0	2.96	1	0
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	0	2.96	1	0
Mental Disorders Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.	0	2.96	1	0
Dizzyness [description not available]	0	4.36	1	1
Dizziness An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.	0	4.36	1	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.05	1	0
Liver Dysfunction [description not available]	0	3.46	1	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	0	3.46	1	1
Liver Diseases Pathological processes of the LIVER.	0	3.46	1	1
Cardiac Diseases [description not available]	0	2.47	2	0
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	0	2.47	2	0
Colorectal Cancer [description not available]	0	4.37	1	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	0	4.37	1	1
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	0	2.47	2	0
Cleft Palate, Isolated [description not available]	0	2.07	1	0
Cleft Palate Congenital fissure of the soft and/or hard palate, due to faulty fusion.	0	7.07	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	0	2.07	1	0
Weight Gain Increase in BODY WEIGHT over existing weight.	0	2.07	1	0
Infection [description not available]	0	2.99	1	0
Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.	0	2.99	1	0

chemdatabank.com

casopitant

Cross-References

Synonyms (28)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (10)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (107)

Molecular Functions (43)

Ceullar Components (38)

Bioassays (89)

Research

Studies (43)

Market Indicators

Research Demand Index: 26.18

Study Types

Clinical Trials (30)

Trial Overview

Trial Outcomes

Percentage of Participants Who Achieved a Complete Response in the Acute Phase of Cycle 1

Percentage of Participants Who Achieved a Complete Response in the Delayed Phase of Cycle 1

Percentage of Participants Who Achieved a Complete Response in the Overall Phase (0-120 Hours) Following Initiation of the First Cycle of an Oxaliplatin Based Moderately Emetogenic Chemotherapy (MEC) Regimen

Percentage of Participants Who Achieved a Complete Response in the Overall Phase of Cycle 2

Single-dose Pharmacokinetic Parameters: Clearance (CL) for Casopitant

Single-dose Pharmacokinetic Parameters: Volume of Distribution (Vdss) for Casopitant

Time to First Anti-emetic Rescue Medication

Time to First Emetic Event

Evaluation of Vital Signs: Mean Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)

Evaluation of Vital Signs: Mean Heart Rate

Maximum Nausea Score, Assessed by a Visual Analogue Scale (VAS)

Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

Number of Participants With Clinical Chemistry Toxicity Grade Shifts From Baseline to Toxicity Grade 3 and 4

Number of Participants With Hematology Toxicity Grade Shifts From Baseline to Toxicity Grade 3 and 4

Percentage of Participants Who Achieved Complete Protection Defined as Complete Responders With no Significant Nausea

Percentage of Participants Who Achieved Total Control, Defined as Complete Responders Who Had no Nausea

Percentage of Participants Who Received Rescue Medication

Percentage of Participants Who Reported Nausea, Defined as a Maximum Score of >= 5 mm on the VAS

Percentage of Participants Who Reported Significant Nausea, Defined as a Maximum Score >= 25 mm on the VAS

Percentage of Participants Who Vomited and/or Retched

Percentage of Participants Whose Daily Life Activities Were Impacted in the Overall Phase of Cycle 1, Assessed by Functional Living Index-Emesis (FLIE) Questionnaire

Single-dose Pharmacokinetic (PK) Parameters: Area Under the Curve (AUC) 0 to Infinity (0-∞), AUC 0 to t (0-t) and AUC 0 to 24 Hours (0-24) for Casopitant; AUC (0-t) and AUC (0-24) for Metabolites GSK525060, GSK517142 and GSK631832

Single-dose Pharmacokinetic Parameters: Maximum Observed Drug Concentration (Cmax) for Casopitant and Metabolites GSK525060, GSK517142 and GSK631832

Single-dose Pharmacokinetic Parameters: Time to Maximum Observed Drug Concentration (Tmax) and Observed Elimination Half-life (t1/2) for Casopitant and Metabolites GSK525060, GSK517142 and GSK631832

Severity of Nausea in the Overall, Acute, and Delayed Phases of Cycle 1 Assessed by a Categorical Scale

Related Drugs (28)

Related Conditions (55)